Compare Procter & Gamble Health with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs PFIZER - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH PFIZER PROCTER & GAMBLE HEALTH/
PFIZER
 
P/E (TTM) x 51.5 33.5 153.8% View Chart
P/BV x 4.7 5.6 83.0% View Chart
Dividend Yield % 10.2 0.6 1,675.5%  

Financials

 PROCTER & GAMBLE HEALTH   PFIZER
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
PFIZER
Mar-18
PROCTER & GAMBLE HEALTH/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3,5492,365 150.1%   
Low Rs1,3011,625 80.1%   
Sales per share (Unadj.) Rs511.4430.3 118.9%  
Earnings per share (Unadj.) Rs61.378.7 77.9%  
Cash flow per share (Unadj.) Rs74.093.2 79.4%  
Dividends per share (Unadj.) Rs440.0020.00 2,200.0%  
Dividend yield (eoy) %18.11.0 1,809.8%  
Book value per share (Unadj.) Rs927.8586.5 158.2%  
Shares outstanding (eoy) m16.6045.75 36.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.6 102.3%   
Avg P/E ratio x39.625.3 156.1%  
P/CF ratio (eoy) x32.821.4 153.1%  
Price / Book Value ratio x2.63.4 76.8%  
Dividend payout %717.925.4 2,825.1%   
Avg Mkt Cap Rs m40,25791,271 44.1%   
No. of employees `0001.12.6 43.1%   
Total wages/salary Rs m1,3133,143 41.8%   
Avg. sales/employee Rs Th7,486.77,484.8 100.0%   
Avg. wages/employee Rs Th1,157.61,195.0 96.9%   
Avg. net profit/employee Rs Th897.21,369.1 65.5%   
INCOME DATA
Net Sales Rs m8,49019,685 43.1%  
Other income Rs m2441,143 21.3%   
Total revenues Rs m8,73420,828 41.9%   
Gross profit Rs m1,4825,003 29.6%  
Depreciation Rs m211663 31.9%   
Interest Rs m04 0.0%   
Profit before tax Rs m1,5145,479 27.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5631,878 29.9%   
Profit after tax Rs m1,0173,601 28.3%  
Gross profit margin %17.525.4 68.7%  
Effective tax rate %37.134.3 108.4%   
Net profit margin %12.018.3 65.5%  
BALANCE SHEET DATA
Current assets Rs m15,34324,167 63.5%   
Current liabilities Rs m1,9609,544 20.5%   
Net working cap to sales %157.674.3 212.2%  
Current ratio x7.82.5 309.1%  
Inventory Days Days4955 88.5%  
Debtors Days Days2829 99.1%  
Net fixed assets Rs m1,2099,514 12.7%   
Share capital Rs m166458 36.3%   
"Free" reserves Rs m15,23526,375 57.8%   
Net worth Rs m15,40126,832 57.4%   
Long term debt Rs m025 0.0%   
Total assets Rs m17,59536,900 47.7%  
Interest coverage xNM1,305.5-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.5 90.4%   
Return on assets %5.89.8 59.2%  
Return on equity %6.613.4 49.2%  
Return on capital %10.320.4 50.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63622 7,304.9%   
Fx outflow Rs m4,3681,489 293.4%   
Net fx Rs m-2,732-1,466 186.3%   
CASH FLOW
From Operations Rs m-1,3043,318 -39.3%  
From Investments Rs m12,697-2,383 -532.8%  
From Financial Activity Rs m-301-1,104 27.2%  
Net Cashflow Rs m11,093-169 -6,583.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 63.9 81.1%  
Indian inst/Mut Fund % 18.2 7.5 242.7%  
FIIs % 1.0 4.9 20.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 23.7 122.8%  
Shareholders   28,591 85,207 33.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   VENUS REMEDIES  ORCHID PHARMA LTD  GSK PHARMA  J.B.CHEMICALS  SHASUN PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Sep 13, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH - DR. REDDYS LAB COMPARISON

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS